The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 09, 2018

Filed:

Apr. 21, 2015
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Yeon-Hee Lim, Piscataway, NJ (US);

Zhuyan Guo, Scotch Plains, NJ (US);

Amjad Ali, Freehold, NJ (US);

Scott D. Edmondson, Clark, NJ (US);

Weiguo Liu, Princeton, NJ (US);

Gioconda V. Gallo-Etienne, Union, NJ (US);

Heping Wu, Edison, NJ (US);

Ying-Duo Gao, Holmdel, NJ (US);

Andrew W. Stamford, Chatham, NJ (US);

Younong Yu, East Brunswick, NJ (US);

Nancy J. Kevin, East Brunswick, NJ (US);

Rajan Anand, Fanwood, NJ (US);

Deyou Sha, Yardley, PA (US);

Santhosh F. Neelamkavil, Edison, NJ (US);

Zahid Hussain, Dayton, NJ (US);

Puneet Kumar, Woodbridge, NJ (US);

Remond Moningka, Jersey City, NJ (US);

Joseph L. Duffy, Cranford, NJ (US);

Jiayi Xu, Marlboro, NJ (US);

Yu Jiang, East Windsor, NJ (US);

Anjan Chakrabarti, Singapore, SG;

Hiroki Sone, Singapore, SG;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 498/20 (2006.01); C07F 9/6561 (2006.01); C07D 487/10 (2006.01); C07D 498/10 (2006.01); C07D 471/10 (2006.01);
U.S. Cl.
CPC ...
C07D 498/20 (2013.01); C07D 471/10 (2013.01); C07D 487/10 (2013.01); C07D 498/10 (2013.01); C07F 9/6561 (2013.01);
Abstract

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.


Find Patent Forward Citations

Loading…